



## INDIAN HEALTH SERVICE National Pharmacy & Therapeutics Committee

**\*\*Fall 2022 NPTC Meeting Update\*\***

**=November 2022=**



The Indian Health Service (IHS) National Pharmacy and Therapeutics Committee (NPTC) held its Fall 2022 meeting on November 1-2<sup>nd</sup>, 2022 in Oklahoma City, OK. All 12 IHS Areas were represented. Mr. Richard Haverkate (Director, IHS HIV/AIDS program) participated and provided valuable input as a subject matter expert. Affiliates from the Department of Defense, Veterans Administration, Bureau of Prisons and United States Coast Guard provided information on formulary updates, clinical experiences, and meeting topics from their respective agencies. The NPTC values the relationships with its field experts, subject matter experts, and federal partners and appreciates the opportunity to host this clinical formulary management meeting at regional locations.

The Fall 2022 NPTC Meeting agenda included reviews of (1) Male Genitourinary Infections, (2) Male Hypogonadism, (3) Erectile Dysfunction, (4) Benign Prostatic Disorders, (5) Prostatic Cancer, and (6) novel HIV Injectable and PrEP Treatments.

### **The resulting action(s) from the NPTC meeting were as follows:**

1. A therapeutic review of Male Genitourinary Infections was provided to the Committee. *Current medications listed on the IHS National Core Formulary (NCF) relevant to the condition include amoxicillin/clavulanate, azithromycin, cephalexin, ceftriaxone, cefdinir, doxycycline, metronidazole, mupirocin, nitrofurantoin and sulfamethoxazole/trimethoprim.* Clinical guidance from the 2022 European Association of Urology (EAU) Guidelines, Sanford Antibiotic Guide, and Hopkins Antibiotic Guide was detailed. Data from numerous RCTs comparing inter- and intra-class antibiotic agents were also shared. Agency pharmacovigilance and pharmaco-economic utilization/trend data added scope to the review. As a result, the NPTC voted to **ADD (1) oral ciprofloxacin, (2) topical clotrimazole and (3) oral fluconazole** to the NCF.
2. A therapeutic review of Male Hypogonadism was also undertaken by the NPTC. *Treatment options listed on the NCF currently relevant to this condition include anastrozole, letrozole, and testosterone (any formulation).* The American Urology Association (AUA) guidelines were central to this evaluation and were supplemented by analyses comparing alternative therapies and differing testosterone formulations in various patient subtypes (i.e., post-pubertal, T2DM, late-onset). Safety data from both published literature and from the IHS National Data Warehouse were reviewed, along with IHS purchasing and utilization trends. Ultimately, the NPTC made **no modifications** to the NCF.
3. A therapeutic review of Erectile Dysfunction was delivered, focusing on non-surgical treatments. *Current medications named to the NCF relevant to this condition include “any Phosphodiesterase 5 Inhibitor”.* Canadian and U.S.-based urological guidelines were presented for committee consideration. Outcomes from meta-analyses evaluating both individual PDE5 inhibitors and collectively (versus other drug classes) were shared. Agency pharmacovigilance and pharmaco-economic utilization/trend data were profiled. Following review and deliberation, the NPTC voted to **REMOVE “any Phosphodiesterase 5 inhibitor”** and **ADD both (1) sildenafil and (2) tadalafil** to the NCF.

4. A therapeutic review of Benign Prostatic Disorders was detailed to the Committee. *Medications listed on the NCF relevant to this condition include doxazosin, finasteride, oxybutynin IR and ER, tamsulosin, and tadalafil.* Contemporary American, Canadian and European urological guidelines were reviewed in detail for pharmacologic recommendations. Meta-analyzed findings from medication class and class agent comparisons were critiqued. Agency pharmacovigilance and pharmaco-economic utilization/trend data were also profiled. The NPTC ultimately made **no modifications** to the NCF.
5. A therapeutic review of Prevention and Treatments in Prostatic Cancer was provided. *Medication relevant to this condition currently listed on the NCF includes finasteride.* Clinical guidance was provided by multiple national and international professional healthcare organizations including the European Society of Medical Oncology, American Society of Clinical Oncology, National Comprehensive Cancer Network, EAU, and the AUA. Outcomes data from drug class and individual agent evaluations were important in the decision. Agency pharmaco-economic utilization/trend data were also profiled. As a result of the comprehensive analysis, the NPTC voted to **ADD leuprolide** to the NCF.
6. A drug class review of Novel Injectable Medications for HIV PrEP and Treatment was presented. *Medications relevant to this condition currently named to the NCF include bicitegravir/emtricitabine/tenofovir alafenamide, dolutegravir, dolutegravir/abacavir/lamivudine, emtricitabine/tenofovir disoproxil fumarate, and raltegravir.* Updated (Sept 2022) HIV treatment guidelines from the U.S. Health and Human Services were presented and served as the primary clinical reference. Targeted literature findings specific to the new HIV injectable PrEP/treatment therapies were shared. Agency pharmacovigilance and pharmaco-economic utilization/trend data added scope to the review. Ultimately, the NPTC made **no modifications** to the NCF.
7. Lastly, the Committee was provided with an abbreviated clinical and pharmaco-economic drug class review of the Histamine-2 Receptor Antagonists. In August 2022, the NPTC voted to remove ranitidine from the NCF. Following this review, the NPTC voted to **ADD famotidine** from the NCF.

---

*\*The next NPTC meeting will be the Winter 2023 Meeting, scheduled for January 24-25, 2023 in Phoenix, AZ. The meeting agenda will include reviews of (1) Treatment of C. Difficile, (2) Inflammatory Bowel Disease, (3) H. Pylori Treatment, (4) Non-Alcoholic Fatty Liver Disease, (5) Cirrhosis and complications, and (6) Chemoprevention of Colorectal Cancer.*

\*\*\*\*\*  
For more information about the NPTC or the National Core Formulary, please visit the [NPTC website](#).  
\*\*\*\*\*